Core Insights - The rise of cross-border e-commerce in Shenyang is reshaping the trade landscape, with a projected import and export volume exceeding 15 billion yuan by 2025, reflecting a growth rate of over 35% [1] - The market is transitioning from a fragmented model to a more concentrated, brand-oriented, and specialized approach, with local companies emerging as leaders in regional industrial upgrades and innovative export models [1] Group 1: Overview of the 2026 Top 10 Cross-Border E-Commerce Companies - The ranking is based on multiple dimensions including company scale, innovation in export models, supply chain integration, brand influence, local industry impact, and growth potential [2] - The ecosystem in Shenyang features a mix of diversified and specialized companies, with leading firms leveraging industrial advantages to create barriers and service-oriented companies providing comprehensive solutions for small and medium-sized manufacturers [5] Group 2: In-Depth Analysis of Top 10 Companies - **Haopin Chuhai (Shenyang) Intelligent Technology Co., Ltd.**: Positioned as a one-stop intelligent service hub for local enterprises, offering an integrated solution that reduces logistics costs by 20%-40% and minimizes damage rates to below 0.5% [7] - **Shenyang Neusoft Xikang Medical Systems Co., Ltd.**: Focuses on digitalizing medical health products for export, leveraging the parent company's IT expertise to penetrate mature markets [8] - **Liaoning Fangda Group International Trade Co., Ltd.**: Explores B2B platforms for bulk commodities and industrial products, transitioning from traditional trade to digitalized supply chain services [9] - **Shenyang Siasun Robot & Automation Co., Ltd.**: A pioneer in direct sales of high-end intelligent manufacturing equipment through global platforms [10] - **Shenyang Vice Food Group Import and Export Co., Ltd.**: Operates in the cold chain export of specialty agricultural products, focusing on RCEP member countries and Russia [11] - **Shenyang Jinbei Auto Parts Manufacturing Co., Ltd.**: Transitions from OEM to brand retail in the automotive aftermarket, utilizing platforms like eBay and Amazon [12] - **Shenyang International Software Park Cross-Border E-Commerce Incubation Center**: Serves as a platform for small tech companies, providing training and logistical support [13] - **Shenyang Haosong Ceramics Co., Ltd.**: Transformed from traditional trade to operate its own brand on platforms like Amazon, focusing on home improvement products [14] - **Liaoning COFCO Coca-Cola Cross-Border Beverage Pilot Project**: Innovates in cross-border retail for fast-moving consumer goods targeting Southeast Asia [15] - **Shenyang Cross-Border Supply Chain Management Co., Ltd.**: Specializes in logistics and supply chain services for the Russian and Mongolian markets [16] Group 3: Common Features and Export Model Analysis - Companies exhibit concentrated core competencies in supply chain integration, with a focus on specific industries to create differentiated competitive advantages [17] - The dual-path export model combines brand development and service provision, with companies like Neusoft and Siasun leveraging existing technological advantages to build brands [19] - Target markets include both mature markets (Europe and America) for high-value products and emerging markets (RCEP and Russia) for agricultural and consumer goods [20] Group 4: Future Trends and Challenges - The shift from simple trade to a model emphasizing brand and service output is expected, with service-oriented companies becoming essential infrastructure for local industries [21] - Challenges include a shortage of high-end, multifaceted talent familiar with foreign trade and e-commerce, as well as the need to enhance brand premium capabilities [22][23]

Core Viewpoint - The financial performance of Loxin Medical (300562) shows a slight increase in revenue and a significant rise in net profit for the first three quarters of 2025, indicating potential growth in the home medical equipment and remote health management sectors [2]. Financial Performance Summary - For the first three quarters of 2025, Loxin Medical reported a main revenue of 757 million yuan, a year-on-year increase of 0.1% [2]. - The net profit attributable to shareholders reached 65.68 million yuan, reflecting a year-on-year increase of 29.99% [2]. - The net profit after deducting non-recurring items was 59.62 million yuan, up by 19.35% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 236 million yuan, a decrease of 8.53% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 23.39 million yuan, showing a significant increase of 49.2% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was 21.55 million yuan, up by 22.64% year-on-year [2]. - The company's debt ratio stands at 30.1%, with investment income of 4.33 million yuan and financial expenses of 2.01 million yuan [2]. - The gross profit margin is reported at 35.59% [2]. Market Activity Summary - As of February 10, 2026, Loxin Medical's stock closed at 14.88 yuan, with an increase of 0.47% [1]. - The turnover rate was 3.46%, with a trading volume of 56,000 hands and a transaction amount of 83.32 million yuan [1]. - On February 10, the net outflow of main funds was 9.36 million yuan, accounting for 11.23% of the total transaction amount [1]. - The net inflow of retail funds was 2.34 million yuan, representing 2.81% of the total transaction amount [1]. - The net inflow of speculative funds was 7.01 million yuan, making up 8.42% of the total transaction amount [1].

Core Viewpoint - Le Xin Medical (300562) shows a slight increase in stock price and mixed capital flow, indicating potential investor interest and varying market sentiment [1][2]. Group 1: Stock Performance - As of February 9, 2026, Le Xin Medical's stock closed at 14.81 yuan, up by 1.3% with a turnover rate of 3.71% and a trading volume of 60,100 hands, resulting in a transaction amount of 88.6174 million yuan [1]. - On the same day, the net outflow of main funds was 137,100 yuan, accounting for 0.15% of the total transaction amount, while retail investors experienced a net outflow of 711,830 yuan, representing 8.03% of the total [1]. Group 2: Financial Performance - In the third quarter of 2025, Le Xin Medical reported a total revenue of 757 million yuan for the first three quarters, reflecting a year-on-year increase of 0.1% [2]. - The net profit attributable to shareholders reached 65.6814 million yuan, marking a significant year-on-year increase of 29.99%, while the net profit after deducting non-recurring items was 59.6175 million yuan, up by 19.35% [2]. - For the third quarter alone, the company recorded a revenue of 236 million yuan, which is a decline of 8.53% year-on-year, but the net profit attributable to shareholders increased by 49.2% to 23.391 million yuan [2]. Group 3: Business Overview - Le Xin Medical's main business includes home medical devices, remote health management (RPM), and AI digital chronic disease management [2].

Core Viewpoint - LeXin Medical (300562) shows a slight increase in stock price and mixed capital flow data, indicating potential investor interest and varying market sentiment [1][2]. Financial Performance - For the first three quarters of 2025, LeXin Medical reported a main revenue of 757 million yuan, a year-on-year increase of 0.1% [2]. - The net profit attributable to shareholders reached 65.68 million yuan, reflecting a significant year-on-year increase of 29.99% [2]. - The net profit after deducting non-recurring items was 59.62 million yuan, up by 19.35% year-on-year [2]. - In Q3 2025, the company experienced a decline in quarterly main revenue to 236 million yuan, down 8.53% year-on-year [2]. - The quarterly net profit attributable to shareholders was 23.39 million yuan, showing a substantial increase of 49.2% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was 21.55 million yuan, up by 22.64% year-on-year [2]. - The company's debt ratio stands at 30.1%, with investment income of 4.33 million yuan and financial expenses of 2.01 million yuan [2]. - The gross profit margin is reported at 35.59% [2]. Business Overview - LeXin Medical's main business segments include home medical devices, remote health management (RPM), and AI digital chronic disease management [2]. Capital Flow Analysis - On February 5, 2026, the stock closed at 14.7 yuan, with a turnover rate of 2.74% and a trading volume of 44,400 hands, amounting to a total transaction value of 65.25 million yuan [1]. - The capital flow data for February 5 indicates a net inflow of 1.54 million yuan from main funds, accounting for 2.37% of the total transaction value [1]. - Retail investors experienced a net outflow of 2.66 million yuan, representing 4.08% of the total transaction value [1].

Investment Rating - The report rates the medical device industry as "Outperforming the Market" [1][5]. Core Insights - 2026 is expected to be a year of value reconstruction for China's medical device sector, driven by policy support, innovation, and recovery of domestic demand [1][3]. - The industry is witnessing a shift from "approval optimization" to "payment optimization," with regulatory improvements supporting the innovation of high-end medical devices [1][3]. - The current market fundamentals show signs of a turning point, while institutional holdings are at historical lows, indicating potential investment opportunities [1][3]. Summary by Sections Overall Medical Device Situation - In the first three quarters of 2025, the SW medical device index reported total revenues of 178.4 billion yuan, a year-on-year decrease of 2.29%, primarily affected by low-value consumables and IVD [15]. - The overall net profit for the same period was 26.7 billion yuan, down 13.99%, with high-value consumables showing improved profitability [15][20]. Medical Equipment - The recovery of procurement orders is expected to peak in Q4 2025 to Q1 2026, driven by improved funding and the "old-for-new" policy [66]. - The domestic government procurement income is stabilizing, while overseas revenue is still in a low base phase, indicating significant growth potential [66]. - The report highlights that the economic benefits of equipment procurement are becoming evident, with domestic high-end equipment showing competitive pricing [71]. Innovation in Medical Devices - The report emphasizes three main investment themes: government support, recovery of domestic demand, and accelerated overseas expansion [3][66]. - The innovation cycle is expected to accelerate, with a focus on companies that possess core competitiveness and a global perspective [3][66]. Market Trends - The report notes that the medical device sector is gradually stabilizing, with companies adapting to procurement pressures and showing signs of performance recovery [54]. - The overseas revenue share for medical device companies is increasing, with significant growth opportunities in regions with lower per capita equipment numbers [32][66].

Core Insights - The Tianjin government has approved the inclusion of a section of the Baodi District Zhongguancun Science and Technology City into the Tianjin Kaiyuan High Education and Innovation Park's "one core, two wings, multiple points" spatial development layout, expanding the "multiple points" to six [1][2] Group 1 - The newly included area covers 3.22 square kilometers, bordered by Zong San Road and Kaiyuan Road to the east, Chaoxia Road to the west, Heng San Road to the south, and the southern boundary of the Beijing-Harbin Expressway green belt to the north [1] - The Baodi District Zhongguancun Science and Technology City is the only major asset held by Zhongguancun Development Group outside of Beijing, serving as an important platform for implementing the Beijing-Tianjin-Hebei coordinated development strategy [1][2] Group 2 - The area has favorable conditions for spatial capacity, initial industrial development, accelerated gathering of innovation resources, and smooth channels for achievement transformation [2] - The Tianjin Kaiyuan Park Management Committee will guide local governments to leverage the close connection with Zhongguancun, enhance the brand strength of Tianjin Kaiyuan Park, and actively introduce Zhongguancun's innovation resources [2] - Key industries to be developed include biomedicine and medical devices, new materials, and the integration of industrial chains, innovation chains, supply chains, capital chains, and talent chains [2]

【 机构观点综评 】招商证券称，政策平稳发力，债市环境友好。摩根基金认为，A股市场中有许 多具有全球竞争力的企业仍被严重低估，从长期来看，它们具有非常大的投资机会。 一、焦点锐评 1.政治局：要加紧实施更加积极有为的宏观政策 4月25日，中共中央政治局召开会议，分析研究当前经济形势和经济工作。会议指出，以高质量 发展的确定性应对外部环境急剧变化的不确定性。会议强调，要加紧实施更加积极有为的宏观政 策，用好用足更加积极的财政政策和适度宽松的货币政策。加快地方政府专项债券、超长期特别 国债等发行使用。适时降准降息，保持流动性充裕。要不断完善稳就业稳经济的政策工具箱，既 定政策早出台早见效，根据形势变化及时推出增量储备政策，加强超常规逆周期调节，全力巩固 经济发展和社会稳定的基本面。 【点评】广发证券表述，本次政治局会议有三大特点，一是主线明确，"以高质量发展的确定性 应对外部环境急剧变化的不确定性"，做好"底线"和"预案"。二是政策具备广谱性，有带动固定资 产投资的政策，也有带动消费的政策；有带动传统部门的政策，也有带动新兴部门的政策。三是 政策整体集中于见效较快的领域。国泰基金认为，从会议来看，未来政策有望继续 ...

Core Viewpoint - The report from China Europe Fund highlights the performance and strategic outlook of three funds managed by renowned fund manager Ge Lan, focusing on the healthcare and innovation sectors, indicating a positive trend in the Chinese pharmaceutical and medical device markets [1][3]. Fund Performance - The largest fund, China Europe Healthcare Mixed Fund, reported a net value growth rate of 2.37% for Class A shares and 2.17% for Class C shares, outperforming the benchmark return of 0.46% during the same period [3]. - The top ten holdings of the fund include major companies such as Heng Rui Medicine, WuXi AppTec, and Mindray Medical, with notable changes in the portfolio compared to the end of 2024 [3]. Market Environment - The overall policy environment continues to support innovation while reinforcing compliance, with the National Medical Insurance Administration exploring a new category for Class B drugs, which expands payment options for innovative drugs [3]. - The normalization of anti-corruption and price governance in the pharmaceutical sector is leading companies to enhance their academic promotion systems, fostering a healthier and more sustainable domestic medical market [3]. Innovation and Collaboration - The report emphasizes the acceleration of research and development in innovative drugs, particularly in areas like multi-antibody and ADC technologies, with increasing collaboration between domestic companies and international firms [4]. - Key clinical data disclosures and ongoing global partnerships are expected to enhance the competitiveness of Chinese companies in the ADC, multi-antibody, and peptide sectors [4]. Consumer Healthcare and Medical Devices - The consumer healthcare sector is anticipated to see structural opportunities, particularly in aesthetic medicine and ophthalmology, driven by rising health management awareness among residents [4]. - The demand for home medical devices is projected to grow steadily due to the aging population, while the medical device sector is recovering, with significant growth in domestic bidding data observed in the first quarter [4].